Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

iSpecimen (ISPC) EBITDA (2020 - 2025)

iSpecimen (ISPC) has 6 years of EBITDA data on record, last reported at -$2.8 million in Q3 2025.

  • For Q3 2025, EBITDA fell 93.12% year-over-year to -$2.8 million; the TTM value through Sep 2025 reached -$11.5 million, down 23.71%, while the annual FY2024 figure was -$12.5 million, 12.61% down from the prior year.
  • EBITDA reached -$2.8 million in Q3 2025 per ISPC's latest filing, down from -$1.0 million in the prior quarter.
  • Across five years, EBITDA topped out at -$942644.0 in Q1 2021 and bottomed at -$6.0 million in Q4 2024.
  • Average EBITDA over 5 years is -$2.4 million, with a median of -$2.2 million recorded in 2023.
  • Peak YoY movement for EBITDA: plummeted 150.19% in 2022, then skyrocketed 50.35% in 2025.
  • A 5-year view of EBITDA shows it stood at -$2.0 million in 2021, then dropped by 7.35% to -$2.1 million in 2022, then crashed by 34.06% to -$2.9 million in 2023, then crashed by 110.62% to -$6.0 million in 2024, then surged by 54.01% to -$2.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$2.8 million in Q3 2025, -$1.0 million in Q2 2025, and -$1.7 million in Q1 2025.